Tag: FH.NE
-
![Today’s Idea: Filament Health (FH.NE) Is All Natural]()
Today’s Idea: Filament Health (FH.NE) Is All Natural
Natural Talent Albert Hofmann was a fun guy, pun intended. More importantly, the Swiss chemist is known for being the first person to synthesize, consume, and learn of the psychedelic effects of lysergic acid diethylamide (LSD). Truly a mad chemist. Furthermore, Hofmann was also the first person to isolate, synthesize, and name the principal psychedelic compounds…
-
![Today’s Idea: Filament Health (FH.NE) Gaining Traction]()
Today’s Idea: Filament Health (FH.NE) Gaining Traction
Problematic Psychedelics? Psychedelics and mental health treatment go together like orange juice and toothpaste. That’s what I would have said five years ago. Prior to the publication of multiple peer-reviewed studies, I adamantly believed psychedelics would melt your brain. In retrospect, that belief is just about as bogus as going to hell for premarital hand-holding.…
-
![Filament Health (FH.NEO) is doing the work to stand out in the psychedelics sector]()
Filament Health (FH.NEO) is doing the work to stand out in the psychedelics sector
I’ll admit that I’m beginning to have my suspicions about the psychedelic sector. The question I’ve started asking when I look at a new psychedelics company is where’s the evidence that they’re actually serious about getting products on shelves? How many startup drug companies at will never see the inside of a laboratory? Why? The…
-
![Filament Health (FH.NEO): fighting the good fight against anxiety and depression]()
Filament Health (FH.NEO): fighting the good fight against anxiety and depression
You’d be hard pressed to find someone who hasn’t been touched by depression or anxiety. Biochemically, they’re considered co-morbid, which means they often happen at the same time and feed off of one another. Depression and anxiety often overlap in terms of neurotransmitters and therefore, they’re often lumped together and treated the same way. And…
-
![Filament Health (FH.NE) releases financials for Q2 of 2021, Tom Kineshanko transitioning from President to Founding Advisor]()
Filament Health (FH.NE) releases financials for Q2 of 2021, Tom Kineshanko transitioning from President to Founding Advisor
Filament Health (FH.NE) to release their unaudited financial results for the second quarter of 2021, a period that ended June 30, 2021. As of June 30, Filament had $7.8 million in cash and cash equivalents. This includes $5 million which was raised through a private placement that closed on June 21. That private placement included…
-
![Filament Health (FH.NE) is experimenting with mushrooms and compounds far beyond just psilocybin]()
Filament Health (FH.NE) is experimenting with mushrooms and compounds far beyond just psilocybin
Mushroom enthusiasts Filament Health (FH.NE) is looking at mushroom compounds far beyond just psilocybin as the company is run by actual mushroom enthusiasts with access to a lot of tools. Filament has the capabilities to experiment and come up with interesting new compounds, extraction methods, and potential future products that probably go far beyond whatever…
